Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment
Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity. We re...
Saved in:
| Published in: | Clinical infectious diseases Vol. 76; no. 3; p. e947 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
08.02.2023
|
| Subjects: | |
| ISSN: | 1537-6591, 1537-6591 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity.
We retrospectively assessed consecutive patients started on linezolid for MDR tuberculosis between 2011 and 2017. The primary outcome was severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates.
SMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95% confidence interval, .30-.49). A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%). The adjusted hazard ratio for SMT was 2.35 (95% confidence interval, 1.26-4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55-4.47; P < .01) for SMT after the first detection of a trough concentration >2 mg/L. In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering elevated trough concentrations did not restore baseline risk.
Linezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR tuberculosis. Pending further prospective evidence, an individual risk-benefit assessment on the continuation of linezolid treatment is warranted in any patient with trough concentrations >2 mg/L. |
|---|---|
| AbstractList | Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity.BACKGROUNDTreatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity.We retrospectively assessed consecutive patients started on linezolid for MDR tuberculosis between 2011 and 2017. The primary outcome was severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates.METHODSWe retrospectively assessed consecutive patients started on linezolid for MDR tuberculosis between 2011 and 2017. The primary outcome was severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates.SMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95% confidence interval, .30-.49). A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%). The adjusted hazard ratio for SMT was 2.35 (95% confidence interval, 1.26-4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55-4.47; P < .01) for SMT after the first detection of a trough concentration >2 mg/L. In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering elevated trough concentrations did not restore baseline risk.RESULTSSMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95% confidence interval, .30-.49). A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%). The adjusted hazard ratio for SMT was 2.35 (95% confidence interval, 1.26-4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55-4.47; P < .01) for SMT after the first detection of a trough concentration >2 mg/L. In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering elevated trough concentrations did not restore baseline risk.Linezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR tuberculosis. Pending further prospective evidence, an individual risk-benefit assessment on the continuation of linezolid treatment is warranted in any patient with trough concentrations >2 mg/L.CONCLUSIONSLinezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR tuberculosis. Pending further prospective evidence, an individual risk-benefit assessment on the continuation of linezolid treatment is warranted in any patient with trough concentrations >2 mg/L. Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity. We retrospectively assessed consecutive patients started on linezolid for MDR tuberculosis between 2011 and 2017. The primary outcome was severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates. SMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95% confidence interval, .30-.49). A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%). The adjusted hazard ratio for SMT was 2.35 (95% confidence interval, 1.26-4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55-4.47; P < .01) for SMT after the first detection of a trough concentration >2 mg/L. In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering elevated trough concentrations did not restore baseline risk. Linezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR tuberculosis. Pending further prospective evidence, an individual risk-benefit assessment on the continuation of linezolid treatment is warranted in any patient with trough concentrations >2 mg/L. |
| Author | Guglielmetti, Lorenzo Le Dû, Damien Caumes, Eric Yazdanpanah, Yazdan Pourcher, Valérie Marigot-Outtandy, Dhiba El-Helali, Najoua Peytavin, Gilles Robert, Jérôme Fréchet-Jachym, Mathilde Mechai, Frédéric Eimer, Johannes Rioux, Christophe |
| Author_xml | – sequence: 1 givenname: Johannes orcidid: 0000-0002-3351-8581 surname: Eimer fullname: Eimer, Johannes organization: INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Équipe 2, Sorbonne Université, Paris, France – sequence: 2 givenname: Mathilde surname: Fréchet-Jachym fullname: Fréchet-Jachym, Mathilde organization: Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France – sequence: 3 givenname: Damien surname: Le Dû fullname: Le Dû, Damien organization: Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France – sequence: 4 givenname: Eric surname: Caumes fullname: Caumes, Eric organization: Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP.Sorbonne Université, Paris, France – sequence: 5 givenname: Najoua surname: El-Helali fullname: El-Helali, Najoua organization: Plateforme de Dosage des Anti-infectieux, Groupe Hospitalier Paris Saint-Joseph, Paris, France – sequence: 6 givenname: Dhiba surname: Marigot-Outtandy fullname: Marigot-Outtandy, Dhiba organization: AP-HP, Service de Maladies Infectieuses, Hôpital Raymond Poincaré, Université de Saint-Quentin en Yvelines, Garches, France – sequence: 7 givenname: Frédéric surname: Mechai fullname: Mechai, Frédéric organization: IAME INSERM UMR-S 1137, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France – sequence: 8 givenname: Gilles surname: Peytavin fullname: Peytavin, Gilles organization: Laboratoire de Pharmacologie-Toxicologie, DMU Biologie et Génomique Médicale (BioGeM), IAME INSERM UMR-S 1137, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France – sequence: 9 givenname: Valérie surname: Pourcher fullname: Pourcher, Valérie organization: Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP.Sorbonne Université, Paris, France – sequence: 10 givenname: Christophe surname: Rioux fullname: Rioux, Christophe organization: AP-HP, Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France – sequence: 11 givenname: Yazdan surname: Yazdanpanah fullname: Yazdanpanah, Yazdan organization: AP-HP, Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France – sequence: 12 givenname: Jérôme surname: Robert fullname: Robert, Jérôme organization: Hôpital Pitié-Salpêtrière, Laboratoire de Bactériologie-Hygiène, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, AP-HP.Sorbonne Université, Paris, France – sequence: 13 givenname: Lorenzo surname: Guglielmetti fullname: Guglielmetti, Lorenzo organization: Hôpital Pitié-Salpêtrière, Laboratoire de Bactériologie-Hygiène, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, AP-HP.Sorbonne Université, Paris, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35717636$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUE1PwzAMjdAQY4MTd5Qjl0LTJP04jvE1aQgE5Ty5qQdBbTKaFBg_g19MgCFxsOxnv_cse0QGxhok5IDFxywu-InSdQhQIpdbZJdJnkWpLNjgXz0kI-ee45ixPJY7ZMhlxrKUp7vkc-KcDWqvraGn6N8QDZ0Z1SE4rOlcG_ywja7pbQOuBTq1RqHx3Y_AUTA19U9Iz_AVG7tqw4jaJb0PsENa2nettF9Tbeh133hdd_1jdIdOOw-BWfYVdqpvbGjQMqz03wZ7ZHsJjcP9TR6Th4vzcnoVzW8uZ9PJPFK8YD4KFxQcmQSmlFB1teRcVlBVCvIsEaJWRcKrVKYsFTLPQS6TDFghYgUgQSmWjMnRr--qsy89Or9otVPYNGDQ9m6RpFkuEsFiEaiHG2pftVgvVp1uoVsv_v6YfAHHA3qR |
| CitedBy_id | crossref_primary_10_7759_cureus_86248 crossref_primary_10_1128_aac_00294_25 crossref_primary_10_3390_pharmaceutics15112543 crossref_primary_10_1002_phar_2769 crossref_primary_10_1093_ofid_ofaf520 crossref_primary_10_1089_mdr_2024_0045 crossref_primary_10_1097_FTD_0000000000001343 crossref_primary_10_1016_j_ijantimicag_2024_107302 crossref_primary_10_1016_j_ijid_2024_01_001 crossref_primary_10_1097_FTD_0000000000001170 crossref_primary_10_1126_sciadv_adt5833 crossref_primary_10_1016_j_ccm_2023_06_012 crossref_primary_10_1128_asmcr_00087_24 crossref_primary_10_3390_ph16111575 crossref_primary_10_1128_aac_00034_24 crossref_primary_10_2147_IDR_S464429 crossref_primary_10_1038_s41586_025_09177_7 |
| ContentType | Journal Article |
| Contributor | Bourgarit, Anne Bonnet, Isabelle Lecorché, Emmanuel Mougari, Faiza Morel, Florence Tunesi, Simone Veziris, Nicolas Andrejak, Claire Ellis-Corbet, Sophie Roux, Anne-Laure Escaut, Lelia Alauzet, Corentine Klement, Elise Wicky, Marie Rivoire, Bénédicte Thouvenin, Guillaume Aubry, Alexandra Bernard, Christine Jaspard, Marie |
| Contributor_xml | – sequence: 1 givenname: Alexandra surname: Aubry fullname: Aubry, Alexandra – sequence: 2 givenname: Isabelle surname: Bonnet fullname: Bonnet, Isabelle – sequence: 3 givenname: Florence surname: Morel fullname: Morel, Florence – sequence: 4 givenname: Nicolas surname: Veziris fullname: Veziris, Nicolas – sequence: 5 givenname: Emmanuel surname: Lecorché fullname: Lecorché, Emmanuel – sequence: 6 givenname: Faiza surname: Mougari fullname: Mougari, Faiza – sequence: 7 givenname: Claire surname: Andrejak fullname: Andrejak, Claire – sequence: 8 givenname: Anne surname: Bourgarit fullname: Bourgarit, Anne – sequence: 9 givenname: Elise surname: Klement fullname: Klement, Elise – sequence: 10 givenname: Bénédicte surname: Rivoire fullname: Rivoire, Bénédicte – sequence: 11 givenname: Guillaume surname: Thouvenin fullname: Thouvenin, Guillaume – sequence: 12 givenname: Simone surname: Tunesi fullname: Tunesi, Simone – sequence: 13 givenname: Marie surname: Wicky fullname: Wicky, Marie – sequence: 14 givenname: Marie surname: Jaspard fullname: Jaspard, Marie – sequence: 15 givenname: Corentine surname: Alauzet fullname: Alauzet, Corentine – sequence: 16 givenname: Lelia surname: Escaut fullname: Escaut, Lelia – sequence: 17 givenname: Sophie surname: Ellis-Corbet fullname: Ellis-Corbet, Sophie – sequence: 18 givenname: Christine surname: Bernard fullname: Bernard, Christine – sequence: 19 givenname: Anne-Laure surname: Roux fullname: Roux, Anne-Laure |
| Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| CorporateAuthor | LZDM group |
| CorporateAuthor_xml | – name: LZDM group |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/cid/ciac485 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-6591 |
| ExternalDocumentID | 35717636 |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 29B 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D AABZA AACGO AACZT AAJKP AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AFYAG AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HW0 HZ~ IOX J21 JLS JSG JXSIZ KAQDR KOP KSI KSN L7B M49 MHKGH MJL ML0 N9A NGC NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y RD5 ROX ROZ RUSNO RW1 RXO SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- 7X8 AHGBF AJBYB |
| ID | FETCH-LOGICAL-c391t-71793e15a1cc4cdbf335babbca87244dc923b656164588a5f27a1940caa5acc12 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 17 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000859896300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-6591 |
| IngestDate | Thu Oct 02 05:35:30 EDT 2025 Thu Apr 03 06:58:07 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | toxicity severe adverse events linezolid multidrug-resistant tuberculosis therapeutic drug monitoring |
| Language | English |
| License | The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c391t-71793e15a1cc4cdbf335babbca87244dc923b656164588a5f27a1940caa5acc12 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-3351-8581 |
| OpenAccessLink | https://hal.science/hal-03909796 |
| PMID | 35717636 |
| PQID | 2678424104 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2678424104 pubmed_primary_35717636 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-02-08 |
| PublicationDateYYYYMMDD | 2023-02-08 |
| PublicationDate_xml | – month: 02 year: 2023 text: 2023-02-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical infectious diseases |
| PublicationTitleAlternate | Clin Infect Dis |
| PublicationYear | 2023 |
| SSID | ssj0011805 |
| Score | 2.5055187 |
| Snippet | Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | e947 |
| SubjectTerms | Antitubercular Agents - adverse effects Drug Monitoring Humans Linezolid - adverse effects Retrospective Studies Tuberculosis, Multidrug-Resistant - drug therapy |
| Title | Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35717636 https://www.proquest.com/docview/2678424104 |
| Volume | 76 |
| WOSCitedRecordID | wos000859896300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qRHzxfpk3IvgatrRNmz6JDsWXjaEV9lZyqwxmO9tV1J_hL_ak7dheBEEohZa0TZOTk-_kfCcHoSuYw0IROoIkjAXEczxOeEINCX1NtScNKEVeJZsIBgM-GoXDZsGtaGiVc51YKWqdKbtG3nFAq8KrwHq4nr4RmzXKelebFBqrqOUClLFSHYwWXgTKKwojDOqA-CykTXweGPEdBV0NP688zn7HltUcc7_939rtoK0GXeKbWhx20YpJ99BGv_Gf76Pvpd7AtzVFC4OKsMx0ozEYpuYrm4w1HgKofhW4Z4Ma02Zn3QKLVGMAjHiJaYSzBD_BZW5wlH3AZ2afeJziKq5X5-ULeTSFhahQMiqlyVU5yeAGjuYE9wP0fH8X9R5Ik5WBKDekMxLYIW0oE1QpT2mZuC6TQkoleABYQSuAjBJQIthhjHPBEicQNPS6SggmlKLOIVpLs9QcI6x8JnyhHVdJsDOhHBxSOpZ263Td0LTR5by1Y5B668oQqcnKIl60dxsd1V0WT-vtOWKXQRV91z_5w9OnaNPmj69o2PwMtRIY8-Ycrav32bjILypxgvNg2P8BF4HY4Q |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+Between+Increased+Linezolid+Plasma+Concentrations+and+the+Development+of+Severe+Toxicity+in+Multidrug-Resistant+Tuberculosis+Treatment&rft.jtitle=Clinical+infectious+diseases&rft.au=Eimer%2C+Johannes&rft.au=Fr%C3%A9chet-Jachym%2C+Mathilde&rft.au=Le+D%C3%BB%2C+Damien&rft.au=Caumes%2C+Eric&rft.date=2023-02-08&rft.issn=1537-6591&rft.eissn=1537-6591&rft.volume=76&rft.issue=3&rft.spage=e947&rft_id=info:doi/10.1093%2Fcid%2Fciac485&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon |